95 related articles for article (PubMed ID: 2258894)
1. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension.
Kirsten R; Heller A; Heintz B; Nelson K
J Hum Hypertens; 1990 Aug; 4(4):461-4. PubMed ID: 2258894
[TBL] [Abstract][Full Text] [Related]
2. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic consequences of long-term antihypertensive treatment with co-dergocrine mesylate/nifedipine in high age groups].
Ritter MM; Richter WO; Schwandt P
Arzneimittelforschung; 1992 Mar; 42(3):311-3. PubMed ID: 1497690
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y
Can J Cardiol; 1998 May; 14(5):682-8. PubMed ID: 9627524
[TBL] [Abstract][Full Text] [Related]
5. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
[TBL] [Abstract][Full Text] [Related]
6. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
Saito I; Saruta T;
Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
[TBL] [Abstract][Full Text] [Related]
7. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
Woodcock BG; Herrmann W; Habedank WD
Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
[TBL] [Abstract][Full Text] [Related]
8. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
Letellier P; Overlack A; Agnes E; Desche P
J Hum Hypertens; 1994 Feb; 8(2):145-9. PubMed ID: 8207741
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
Svetkey LP; Weinberger MH; Gavras H; Gavras I; Brown TS; Deterding J; Klotman PE
J Clin Hypertens; 1987 Dec; 3(4):579-88. PubMed ID: 3330988
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of mild to moderate hypertension. Efficacy and tolerance of Amlodipine in comparison with the combination nifedipine/mefruside].
Höfling B; Häringer E; Herrmann W; Pieske H; Pieske R; Philippi M
Fortschr Med; 1991 May; 109(15):327-30. PubMed ID: 1830287
[TBL] [Abstract][Full Text] [Related]
11. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.
Zanchetti A
J Hypertens Suppl; 1994 Jul; 12(5):S23-7. PubMed ID: 7965282
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
Harder S; Rietbrock S; Thürmann P
Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension.
Toal CB
Can J Cardiol; 1997 Oct; 13(10):921-7. PubMed ID: 9374948
[TBL] [Abstract][Full Text] [Related]
14. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
Zanchetti A
Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine.
Poulter N; Thompson AV; Sever PS
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S53-6. PubMed ID: 2455140
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
Fagan TC; Haggert BE; Liss C
Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251
[TBL] [Abstract][Full Text] [Related]
18. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure response in 24 hours in patients with high blood pressure treated with two nifedipine formulations once a day.
Rodríguez-Roa E; Octavio A; Mayorca E; Castro P; Miranda R; Valecillo E; González M
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S151-5. PubMed ID: 11986915
[TBL] [Abstract][Full Text] [Related]
20. [On the clinical evaluation of therapy with nifedipine in association with various anithypertensive drugs (author's transl)].
Laaser U; Meurer KA; Kaufmann W
Arzneimittelforschung; 1977; 27(3):676-81. PubMed ID: 577445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
